Tag: American Diabetes Association (ADA) 85th Scientific Sessions 2025

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans...

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The...

The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsAmerican Diabetes Association (ADA) 85th Scientific Sessions 2025

《The 36th Golden Melody Awards》

Form 8.5 (EPT/RI) – Dowlais Group plc

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT Q2 2025

Tag: American Diabetes Association (ADA) 85th Scientific Sessions 2025

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us